Clavis raises $25.7 million

Clavis Pharma ASA (OSE:CLAVIS) raised NOK154 million ($25.7 million) through the sale of 4.4 million shares at NOK35 per share in a private placement to new and existing institutional investors. ABG Sundal Collier and Carnegie were joint lead managers and joint bookrunners. Clavis' Elacytarabine ( CP-4055), a Lipid Vector Technology (LVT) derivative of cytarabine (Ara-C), is in Phase III testing to treat late-stage acute myelogenous leukemia (AML). ...